Landos Biopharma announced that an abstract on its Phase 1b Study to evaluate safety, tolerability, pharmacokinetics and clinical efficacy of the Nucleotide-binding oligomerization domain, Leucine rich Repeat containing X1 agonist NX-13 in Ulcerative Colitis, was accepted for poster presentation by the 18th Congress of the European Crohn’s and Colitis Organization, ECCO. "We are excited and appreciative that the ECCO Clinical Research Committee has selected Landos’ NX-13 abstract for poster presentation and look forward to continuing to advance this potential new treatment through the clinic," noted Dr. Fabio Cataldi, Executive Vice-President & Chief Medical Officer at Landos. "Our team is working hard to advance the upcoming NX-13 Phase 2 proof-of-concept clinical trial. And with a strong data foundation, we are confident in our path forward and are excited about the potential of NX-13 to potentially transform the current treatment paradigm for moderate-to-severe UC patients."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on LABP:
- Landos Biopharma Announces Acceptance of Abstract on NX-13 Phase 1b Study in Ulcerative Colitis at 18th Annual Congress of the European Crohn’s and Colitis Organization
- Jefferies cuts Landos to Underperform with no major catalysts seen for 2 years
- Landos Biopharma downgraded to Underperform from Hold at Jefferies
- Landos Biopharma provides update on clinical development plans
- Landos Biopharma announces $16.7M private placement financing
